Theobromine inhibits sensory nerve activation and cough Omar S. Usmani * , Maria G. Belvisi † ,1 , Hema J. Patel † , Natascia Crispino † , Mark A. Birrell † , Márta Korbonits ‡ , Dezső Korbonits § and Peter J. Barnes * * Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College London, London, UK; † Respiratory Pharmacology Group, National Heart and Lung Institute, Imperial College London, London, UK; ‡ Department of Endocrinology, St. Bartholomew’s Hospital, London, UK; and § Chinoin Co. Ltd., Budapest, Hungary 1 Correspondence: Respiratory Pharmacology Group, Department of Airway Diseases, National Heart and Lung Institute, Dovehouse St., London SW3 6LY, UK. E-mail: m.belvisi@imperial.ac.uk <h3>SPECIFIC AIMS</h3> Cough is a condition that affects the vast majority of people at some point in their lives and is the most common complaint for which medical attention is sought. Currently, no effective treatment exists. The aim of this study was to investigate the utility of a novel antitussive called theobromine, a methylxanthine derivative present in cocoa and chocolate, on cough and airway sensory nerve function in humans. <h3>PRINCIPAL FINDINGS</h3> <h3>1. Theobromine as a potential antitussive</h3> Several synthetic antitussives are characterized by the presence of a
/lp/fed-of-american-socs-for-experimental-biology/theobromine-inhibits-sensory-nerve-activation-and-cough-HXzdGY0PBy